Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
You may also be interested in...
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Calithera’s most advanced oncological asset, telaglenastat, has failed in yet another indication, prompting the company to fall back on candidates in-licensed from Takeda just last month.
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.